ÖZET
Diyabet ve Alzheimer hastalığı (AH) arasındaki ilişkiyi işaret eden epidemiyolojik çalışmaların artmasının ardından, Tip 2 diyabetin AH patolojisinin oluşumunda bir risk faktörü olduğu bildirilmiştir. Beyinde gelişen insülin rezistansı, insülin sinyal iletim sisteminde ve glukoz metabolizmasında bozuklukların meydana gelmesi en olası patofizyolojik sebepler arasında gösterilmiştir. Tip 2 diyabet modeli sıçanlarda fosfo tau ve Aβ gibi AH belirteçlerinin arttığı bununla beraber insülin reseptör (IR) sinyalinin ve insülin benzeri büyüme faktörü-1 reseptörlerinin (IGF-1R) azaldığı bildirilmiştir. Ayrıca AH’de insülin reseptör yolağında yer alan fosfo-AKT (protein kinaz B) ve fosfo-glikojen sentaz kinaz-3β (GSK3β) gibi hücre içi bileşenlerinin azaldığı kanıtlanmıştır. Tip 2 diyabet ve AH’deki patolojik süreçlerin altında yatan ortak moleküler mekanizmalar nedeniyle, AH tedavisinde diyabette endike olan tedavi protokolleri kullanılmaya başlanmıştır.
References
1
Haan MN. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer’s disease. Nature clinical practice Neurology 2006;2:159-66.
2
Kolarova M, García-Sierra F, Bartos A, Ricny J,Ripova D. Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis 2012;2012:1-13.
3
Striepens N, Scheef L, Wind A, Popp J, Spottke A, Cooper-Mahkorn D, et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord 2010;29:75-81.
4
Querfurth HW, LaFerla FM. Mechanisms of disease. N Engl J Med 2010;362:329-44.
5
Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 2002;109:341-60.
6
Laws SM, Hone E, Gandy S,Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer’s disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003;84:1215-36.
7
ME EEV,DERNEĞİ A. TANI ve TEDAVİ KILAVUZU.
8
Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, et al. IDF DIABETES ATLAS. 2013.
9
Chatterjee S, Mudher A. Alzheimer’s disease and type 2 diabetes: A critical assessment of the shared pathological traits. Front Neurosci 2018;12:383.
10
Nday CM, Eleftheriadou D, Jackson G. Shared pathological pathways of Alzheimer’s disease with specific comorbidities: current perspectives and interventions. J Neurochem 2018;144:360-89.
11
Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang H-Y, Ahima RS, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 2018;14:168.
12
Erbaş O. Is Alzheimer’s disease, type 3 diabetes? D J Med Sci 2015;1:48-51.
13
McLean FH, Grant C, Morris AC, Horgan GW, Polanski AJ, Allan K, et al. Rapid and reversible impairment of episodic memory by a high-fat diet in mice. Sci Rep 2018;8:1-9.
14
Folch J, Ettcheto M, Busquets O, Sánchez-López E, Castro-Torres RD, Verdaguer E, et al. The implication of the brain insulin receptor in late onset Alzheimer’s disease dementia. Pharmaceuticals (Basel) 2018;11:11.
15
De la Monte SM,Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008;2:1101-13.
16
Devaskar SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK, Zahm DS. Insulin gene expression and insulin synthesis in mammalian neuronal cells. J Biol Chem 1994;269:8445-54.
17
Steen E, Terry BM, J Rivera E, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease--is this type 3 diabetes? J Alzheimers Dis 2005;7:63-80.
18
Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. Eur J Pharmacol 2013;719:170-9.
19
Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005;8:247-68.
20
Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316-38.
21
Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010;31:224-43.
22
Zhang Y, Huang N-q, Yan F, Jin H, Zhou S-y, Shi J-s, et al. Diabetes mellitus and Alzheimer’s disease: GSK-3 as a potential link. Behav Brain Res 2018;339:57-65.
23
Plum L, Belgardt BF, Brüning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest 2006;116:1761-6.
24
McNay EC, Pearson-Leary J. GluT4: A central player in hippocampal memory and brain insulin resistance. Exp Neurol 2020;323:113076.
25
Zhong KL, Chen F, Hong H, Ke X, Lv YG, Tang SS, et al. New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer’s disease. Metab Brain Dis 2018;33:1009-18.
26
Zhang J, Chen C, Hua S, Liao H, Wang M, Xiong Y, ve ark. An updated meta-analysis of cohort studies: diabetes and risk of Alzheimer’s disease. Diabetes Res Clini Pract 2017;124:41-7.
27
Isik AT, Celik T, Ulusoy G, Ongoru O, Elibol B, Doruk H, et al. Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model. Age (Dordr) 2009;31:39-49.
28
Ashpole NM, Sanders JE, Hodges EL, Yan H,Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging brain. Exp Gerontol 2015;68:76-81.
29
Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R,Cowburn RF. Akt activity in Alzheimer’s disease and other neurodegenerative disorders. Neuroreport 2004;15:955-9.
30
Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC,Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004;53:474-81.
31
Li Z-g, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007;56:1817-24.
32
Simsir IY, Soyaltin UE,Cetinkalp S. Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease. Diabetes Metab Syndr 2018;12:469-75.
33
Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker LD, et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement 2015;11:504-10.e1.
34
Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML,Srikanth V. Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology 2015;85:1123-30.
35
Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, et al. Glucose levels and risk of dementia. N Engl J Med 2013;369:540-8.
36
Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis 2010;37:67-76.
37
Angelopoulou E, Piperi C. DPP-4 inhibitors: a promising therapeutic approach against Alzheimer’s disease. Ann Transl Med 2018;6:255.
38
Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009;66:315-22.
39
Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM. Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev 2016;64:272-87.
40
Avgerinos KI, Kalaitzidis G, Malli A, Kalaitzoglou D, Myserlis PG,Lioutas V-A. Intranasal insulin in Alzheimer’s dementia or mild cognitive impairment: a systematic review. J Neurol 2018;265:1497-510.
41
Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002;51:1256-62.
42
Malek-Ahmadi M, Beach T, Obradov A, Sue L, Belden C, Davis K, ve ark. Type 2 diabetes is associated with increased Alzheimer’s disease neuropathology in ApoE 4 Carriers. Curr Alzheimer Res 2013;10:654-9.
43
Starks EJ, Patrick O’Grady J, Hoscheidt SM, Racine AM, Carlsson CM, Zetterberg H, et al. Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOE 4 Carriers. J Alzheimers Dis 2015;46:525-33.
44
Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST. Neuroprotective actions of glucagon-like peptide-1 (GLP-1) analogues in Alzheimer’s and Parkinson’s diseases. CNS Drugs 2019;33:209-23.
45
www.clinicaltrials.gov Af. Retrieved 25.04.2020
